Mesirow Financial Investment Management Inc. Purchases 3,722 Shares of AbbVie Inc. $ABBV

Mesirow Financial Investment Management Inc. raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% during the 3rd quarter, Holdings Channel reports. The fund owned 162,499 shares of the company’s stock after purchasing an additional 3,722 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in AbbVie were worth $37,624,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Brighton Jones LLC raised its position in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares during the last quarter. Advisory Alpha LLC raised its holdings in shares of AbbVie by 13.9% in the second quarter. Advisory Alpha LLC now owns 5,731 shares of the company’s stock worth $1,064,000 after buying an additional 701 shares during the period. Finally, Austin Private Wealth LLC lifted its stake in shares of AbbVie by 13.9% during the 2nd quarter. Austin Private Wealth LLC now owns 4,781 shares of the company’s stock worth $887,000 after acquiring an additional 585 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on ABBV. Barclays started coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Morgan Stanley increased their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Price Performance

Shares of NYSE ABBV opened at $227.01 on Thursday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The business has a fifty day moving average price of $224.22 and a 200 day moving average price of $222.70. The stock has a market capitalization of $401.38 billion, a P/E ratio of 96.19, a price-to-earnings-growth ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $380 million investment to build two new API (active pharmaceutical ingredient) manufacturing facilities at its North Chicago campus — a multi‑year project expected to boost U.S. supply security, support production for obesity and other franchises, and create several hundred jobs (facilities targeted to be operational by 2029). AbbVie to build 2 API plants in Illinois
• Positive Sentiment: The FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination for first‑line treatment of CLL — the first all‑oral, fixed‑duration regimen for previously untreated patients, which should expand market opportunity and support oncology revenue growth. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a note that can improve sentiment among institutional investors. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — supportive real‑world evidence can aid uptake, but the near‑term revenue impact is limited. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: AbbVie will present at the TD Cowen Health Care Conference on March 3 — a routine investor event that could provide incremental disclosure but not guaranteed news. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Multiple retail and dividend‑oriented writeups are highlighting AbbVie’s high yield and growing payout — this supports income‑investor interest but is unlikely to move the stock materially on its own. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Negative Sentiment: Analysts and research notes flag execution risk and intensifying competition across parts of AbbVie’s pipeline and immunology portfolio — these concerns are constraining upside in some models and tempering investor enthusiasm. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Valuation and momentum considerations (ABBV trades with a high P/E and recently near its 52‑week range) plus below‑average intraday volume can prompt profit‑taking even when company news is constructive.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.